Nicotinic acid is a vasodilator and anti-pellag agent.
Release form and composition
- Tablets (10 each in a blister; jars, in a cardboard bundle of 1 bank);
- Solution for injection (1 ml in ampoules, 5 ampoules in blisters, in a cardboard bundle 1 or 2 packs).
Active ingredient - nicotinic acid:
- In 1 tablet - 50 mg;
- In 1 ml of solution - 10 mg.
Indications for use
- Hypo-and vitamin PP deficiency;
- Hartnup disease (a hereditary disease characterized by impaired absorption of certain amino acids, including tryptophan).
Nicotinic acid is also used in combination therapy for the following diseases:
- Ischemic stroke;
- Neuritis of the facial nerve;
- Obliterating vascular diseases of the extremities (Raynaud’s disease and endarteritis obliterans);
- Diabetes mellitus and its complications, such as microangiopathy and diabetic polyneuropathy.
- Cirrhosis of the liver;
- Exacerbation of gastric ulcer and 12 duodenal ulcer;
- Decompensated diabetes;
- Hypersensitivity to nicotinic acid.
Relative (the drug should be used with extreme caution due to the risk of complications):
- Peptic ulcer and 12 duodenal ulcer in remission;
- Hyperacid gastritis;
Dosing and Administration
Tablets should be taken orally after meals.
- Prevention: adults - 15-25 mg, children - 5-20 mg per day;
- Treatment of pellagra: adults - 100 mg 2-4 times a day, children - 5-50 mg 2-3 times a day;
- Other diseases: adults - 20-100 mg, with hypercholesterolemia, the daily dose may be increased to 2000-3000 mg, children - 5-30 mg 2-3 times a day.
When pellagra is administered intramuscularly, intravenously or subcutaneously, 1 ml 2-3 times per day in a course of 10-15 days.
In ischemic stroke, nicotinic acid is slowly injected intravenously in doses of 10 mg.
For other indications, it is usually prescribed 10 mg 1-2 times a day for 10-15 days.
The maximum permissible single dose for adults is 100 mg, daily - 300 mg.
In Hartnup disease, the daily therapeutic dose may range from 40 to 200 mg.
- Cardiovascular system: hyperemia of the skin of the face and upper half of the body, rush of blood to the scalp, headache, heat sensation, orthostatic hypotension, collapse; with rapid intravenous administration - dizziness, a significant reduction in blood pressure;
- Central and peripheral nervous system: dizziness, paresthesias;
- Metabolism: with long-term use - asthenia, reduced glucose tolerance, hyperuricemia, increased blood levels of aminotransferase, lactate dehydrogenase, alkaline phosphatase;
- The digestive system: with long-term use - fatty degeneration of the liver;
- Other: allergic reactions (pruritus, skin rash, urticaria, wheeled breathing);
- Local reactions after intramuscular and subcutaneous administration: pain.
During treatment, liver function should be monitored. To prevent complications, include products containing methionine (for example, cottage cheese) in the diet, or take lipoic acid, methionine and other lipotropic drugs.
During the period of therapy, it is recommended to refrain from driving and performing potentially hazardous activities that require reaction speed and high concentration of attention.
- Sulfonylurea: increases the level of glucose in the blood;
- Lovastatin: risk of myopathy;
- Neomycin: reduces its toxicity, prevents them from reducing the concentration of high-density lipoprotein and cholesterol.
Special care should be taken when using ascorbic acid, anticoagulants and antihypertensive drugs at the same time.
Terms and conditions of storage
Store at temperatures up to 25 ºC in a dry, dark place out of reach of children.
The shelf life of the solution - 3 years, tablets - 4 years.